Jumping ahead of AstraZeneca, AbbVie and J&J get a green light to market Imbruvica/Rituxan combo for rare lymphoma

Building on some solid data, AbbVie and J&J today landed an FDA OKto sell a chemo-free combination of their BTK inhibitor Imbruvica with Roche’s Rituxan for a rare and incurable type of non-Hodgkin’s lymphoma.